{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The event will be death due to reasons other than disease. The competing risk for NRM will be death due to disease. The cumulative incidence curve accounting competing risks will be generated to estimate the cumulative incidence rate at various time points.","groups":[{"description":"Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic stem cell transplantation\n\nCyclophosphamide: Given IV\n\nDaratumumab: Given IV\n\nFludarabine: Given IV\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nTacrolimus: Given PO or IV","id":"OG000","title":"Treatment (Conditioning Regimen, Stem Cell Transplant)"}],"populationDescription":"Due to low patient accrual to study unable to collect and analyze data","reportingStatus":"POSTED","timeFrame":"From the date of transplant to date of death, assessed at 2 years","title":"2-year Cumulative Incidence of TRM","type":"SECONDARY"}